Alliance for Pandemic Preparedness

June 19, 2020

Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality

Category:

Topic:

  • A retrospective cohort study of 4,480 patients with COVID-19 using data from the Danish national administrative registries found that prior use of ACE inhibitors and angiotensin receptor blockers (ACEI/ARBs) was not associated with higher mortality from COVID-19.  
  • [EDITORIAL NOTE: The article was accompanied by a JAMA editorial that concluded that when there is a clinical indication for their use, ACEI/ARBs should not be discontinued in patients with COVID-19, unless the drugs cannot be tolerated due to hemodynamic instability. However, we note that adjusted models showed a significant or nearly significant modest association with severe COVID-19] 

Fosbøl et al. (June 19, 2020). Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality. JAMA. https://doi.org/10.1001/jama.2020.11301